A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis

Hepatology

Volumn 50, Issue 4, 2009, Pages 1184-1193

  Hung, Tzu Min ^a   Chang, Shin C ^a   Yu, Wei Hsuan ^a   Wang, Yu Wen ^b   Huang, Cheng ^a   Lu, Shao Chun ^a   Lee, Po Huang ^b   Chang, Ming Fu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; GLYCINE; MATRILYSIN; BIOLOGICAL MARKER; CD151 ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CASE CONTROL STUDY; CELL MOTILITY; CONTROLLED STUDY; ENZYME LOCALIZATION; ENZYME RELEASE; EXTRACELLULAR SPACE; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; CELL MEMBRANE; GENETIC PREDISPOSITION; GENETICS; ITO CELL; LIVER TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

ADULT; AGED; ANTIGENS, CD; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL MEMBRANE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 70350075399     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23137     Document Type: Article

References (33)

1. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
2. Chedid A, Ryan LM, Dayal Y, Wolf BC, Falkson G. Morphology and other prognostic factors of hepatocellular carcinoma. Arch Pathol Lab Med 1999;123:524-528.
3. Friedman SL. Liver fibrosis: from bench to bedside. J Hepatol 2003;38:S38-S53.
4. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-832.
5. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134:1655-1669.
6. Benyon RC, Arthur MJP. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001;21:373-384.
7. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999;31:9-16.
8. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. HEPATOLOGY 2003;37:493-503.
9. Yee LJ, Tang J, Herrera J, Kaslow RA, van Leeuwen DJ. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000;1:386-390.
10. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, et al. Host genetic factors influence disease progression in chronic hepatitis C. HEPATOLOGY 2000;31:828-833.
11. Muhlbauer M, Bosserhoff AK, Hartmann A, Thasler WE, Weiss TS, Herfarth H, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-1093.
12. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 2005;37:835-843.
13. Albers I, Hartmann H, Bircher J, Creutzfeldt W. Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-276.
14. Lee SG, Hwang S. How I do it: assessment of hepatic functional reserve for indication of hepatic resection. J Hepatobiliary Pancreat Surg 2005;12:38-43.
15. Chiesa R, Donato F, Tagger A, Favret M, Ribero ML, Nardi G, et al. Etiology of hepatocellular carcinoma in Italian patients with and without cirrhosis. Cancer Epidemiol Biomarkers Prev 2000;9:213-216.
16. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore. Curr Opin Cell Biol 2001;13:534-540.
17. Ii M, Yamamoto H, Adachi Y, Maruyama Y, Shinomura Y. Role of matrix metalloproteinase-7 (Matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis. Exp Biol Med 2006;231:20-27.
18. Yu WH, Woessner JF Jr. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase-7). J Biol Chem 2000;275:4183-4191.
19. Yamamoto K, Higashi S, Kioi M, Tsunezumi J, Honke K, Miyazaki K. Binding of active matrilysin to cell surface cholesterol sulfate is essential for its membrane-associated proteolytic action and induction of homotypic cell adhesion. J Biol Chem 2006;281:9170-9180.
20. Shiomi T, Inoki I, Kataoka F, Ohtsuka T, Hashimoto G, Nemori R, et al. Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151. Lab Invest 2005;85:1489-1506.
21. Engling A, Backhaus R, Stegmayer C, Zehe C, Seelenmeyer C, Kehlenbach A, et al. Biosynthetic FGF-2 is targeted to non-lipid raft microdomains following translocation to the extracellular surface of CHO cells. J Cell Sci 2002;115:3619-3631.
22. Bissell DM. Hepatic fibrosis as wound repair: a progress report. J Gastroenterol 1998;33:295-302.
23. Dunsmore SE, Saarialho-kere UK, Roby JD, Wilson CL, Matrisian LM, Welgus HG, et al. Matrilysin expression and function in airway epithelium. J Clin Invest 1998;102:1321-1331.
24. McGuire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 2003;162:1831-1843.
25. Afdhal NH, Nunes D. Evaluation of liver fibrosis: A concise review. Am J Gastroenterol 2004;99:1160-1174.
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:1449-1457.
27. Lichtinghagen R, Michels D, Haberkorn CI, Arndt B, Bahr M, Flemming P, et al. Matrix metalloproteinase (MMP)-2, MMP-7, and tissue inhibitor of metalloproteinase-1 are closely related to the fibroproliferative process in the liver during chronic hepatitis C. J Hepatol 2001;34:239-247.
28. Huang CC, Chuang JH, Chou MH, Wu CL, Chen CM, Wang CC, et al. Matrilysin (MMP-7) is a major matrix metalloproteinase upregulated in biliary atresia-associated liver fibrosis. Mod Pathol 2005;18:941-950.
29. Yang C, Zeisberg M, Mosterman B, Sudhakar A, Yerramalla U, Holthaus K, et al. Liver fibrosis: Insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003;124:147-158.
30. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P. Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 β3 chain. Cancer Res 2006;66:11228-11237.
31. Sternlicht MD, Werb Z. How matrix mtalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
32. Berton A, Selvais C, Lemoine P, Henriet P, Courtoy PJ, Marbaix E, et al. Binding of matrilysin-1 to human epithelial cells promotes its activity. Cell Mol Life Sci 2007;64:610-620.
33. Mazzocca A, Carloni V, Sciammetta SC, Cordella C, Pantaleo P, Caldini A, et al. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J Hepatol 2002;37:322-330.